Dosage and usage of Panobinostat

Panobinostat (Panobinostat) is a histone deacetylase inhibitor mainly used to treat multiple myeloma (Multiple Myeloma). Its usage and dosage usually need to be individually adjusted based on the patient's specific situation and the doctor's recommendations.

Pabinostat is usually administered in oral form, and patients should use it according to a specific medication regimen under the guidance of a doctor. In the treatment of multiple myeloma, panobinostat is often used as part of a combination treatment regimen with other anti-cancer drugs such as prednisone and rituximab (Pano-BD regimen) to improve the overall effect of treatment.

Pobinostat 20mg each time, taken orally, every 1 day1 times, continuously pan>2 weeks, drug withdrawal 1 week, every 21 days is a course of treatment; continuous medication span>8 courses of treatment (24 weeks). If the patient's treatment effect is good and no serious or medically significant toxicity occurs, additional treatment may be considered 8 courses of treatment; the longest treatment with this product is 16 courses (48 weeks).

Dosage is usually determined based on the patient's medical condition, severity of disease, and other possible drug interactions. Doctors will adjust the dose of panobinostat based on the patient's liver function, heart condition and other factors to ensure that the patient can obtain the best therapeutic effect while minimizing the risk of adverse reactions.

Patients need to follow the doctor's advice while taking panobinostat and take the medicine according to the prescribed time and dosage. At the same time, doctors usually monitor patients' blood indicators regularly to evaluate the effectiveness of treatment and adjust dosage. This personalized treatment plan helps ensure that patients receive maximum efficacy while reducing the risk of adverse effects while receiving panobinostat.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.